Practical Roadmap for Starting and Maintaining Subcutaneous Foslevodopa/Foscarbidopa Infusion
This industry-sponsored expert narrative review translates pivotal trial data and early real-world experience into operational guidance on patient selection, dose conversion, titration, and infusion site management for pharmacists supporting advanced Parkinson's disease device-aided therapy.
📅 Journal publication: Jul 2026(online Jan 16, 2026)·Last updated: Nov 20, 2026
New infusion approach eases motor fluctuations in advanced Parkinson's disease.
Foslevodopa/foscarbidopa provides a novel delivery method to manage advanced Parkinson's disease with continuous levodopa delivery. The infusion improves motor fluctuations and quality of life, with manageable infusion site events and systemic adverse effects. Guidance on real-world use suggests effective outpatient initiation and management, but highlights the need for patient and team education. Continuous subcutaneous infusion of foslevodopa/foscarbidopa offers stable symptom control for advanced Parkinson's disease.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Chaudhuri KR, Bergmans B, Freire-Alvarez E, Hopes L, Kern DS, Kirsner RS, Lazzeri G, Mendes-Bastos P, Nishikawa N, Odin P, Poplawska-Domaszewicz K, Pahwa R, Ramot Y, Seppi K, Warnecke T, Wiggins R, Shah MB, Kukreja P, Fritz B, Onuk K, Isaacson SH
Citation:Chaudhuri KR, Bergmans B, Freire-Alvarez E, et al. Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease. Movement disorders clinical practice. 2026;13(7):1601-1611. doi:10.1002/mdc3.70489